Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Pentacel vs Separate Components in Infants
NCT00255047Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2005
- Primary completion
- Jul 2008
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pertactin in diphtheria, Tetanus, pertussis and 2 more (4 arms), sponsored by Sanofi. Primary endpoints: Percentage of Participant Responding to Pertussis Antigens Post-Dose 3, Percentage of Participants With a Four-fold Rise in Pertussis Antigens Post-Dose 3 and 1 more. Started Nov 2005; status: completed.
02
Drugs
pertactin
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT00255047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255047.